Tatiana Pont Carteret

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ.

Calibra Medical LLC develops and markets medical devices and technologies in the diabetes sector. Its products include finesse and insulin delivery devices. The company was founded by Daniel Hawkins and Clifton A. Alferness in 2004 and is headquartered in Wayne, PA.

Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

The Academy of Medical Sciences was founded in 1998 and provides biomedical and health research services. The non-profit company is based in London, UK.

The Association of the British Pharmaceutical Industry is a non-profit organization, which engages in the research and development of medicines. It focuses on biosciences. The company is headquartered in London, the United Kingdom.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Part of GSK Plc, GlaxoSmithKline AG is a Swiss company.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Urrma AG is a Swiss pharmaceutical company that focuses on research and development, manufacturing, and marketing of pharmaceutical products. The private company is based in Basel, Switzerland.

The British Pharmacological Society is a charity and membership organization that aims to promote and advance the field of pharmacology. The private company is based in London, UK. The British company leads the way in researching and applying pharmacology worldwide. The company was founded in 1931. Rachel Lambert-Forsyth has been the CEO of the company since 2020.

Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland.

Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA.

PharmaSens AG develops medical devices for diabetes care. The private company is based in Reinach, Switzerland.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.

Quintessa Investment acts as alternative investment manager. It is engaged in financial investment activities. The company was founded on January 13, 2011 and is headquartered in Seoul, South Korea.

pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea.

Royal Pharmaceutical Society operates as a professional membership body for pharmacists and pharmacy. The private company is based in London, UK. and has subsidiaries in United Kingdom.

Neuroscience Research Centre operates a science research center that supports and facilitates research in all areas of clinical neuroscience. The private company is based in Santa Barbara.

Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million.

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.